{
AstraZeneca PLC

Companies

}
Symbol AZN
Name AstraZeneca PLC
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Pharmaceuticals
Market NASDAQ Global Select
Country United Kingdom
State
City Cambridge
Zipcode CB2 0AA
Website http://www.astrazeneca.com
Track all markets on TradingView
ubs upgrades astrazeneca to neutral amid uncertainties in china
UBS has upgraded AstraZeneca"s shares from "Sell" to "Neutral," maintaining a target price of 11,300 pence following a significant drop in the company"s stock. Analyst Matthew Weston notes considerable uncertainties in China but believes the local pharmaceutical authority will remain supportive of AstraZeneca. His earnings estimates, which are below consensus, limit a more favorable rating for the shares.
MarketScreener
British Pound Sterling AstraZeneca PLC GBR Matthew Weston
TradFi, Market Report
07:43 20.11.2024
AstraZeneca"s Diverse Revenue Streams and Global Market Presence
AstraZeneca PLC, a leading global pharmaceutical group, generates 95.6% of its revenue from product sales, primarily in oncology (39.2%) and cardiovascular, renal, and metabolic diseases (24.2%). The company’s sales are geographically distributed with 45.3% from the Americas, 21.2% from Europe, and 26.1% from Africa-Asia-Australia. Collaboration revenues account for the remaining 4.4%.
Zonebourse
United States Dollar AstraZeneca PLC GBR
TradFi, Market Report
07:38 20.11.2024
ubs upgrades astrazeneca to neutral with target price of 11300 pence
UBS has upgraded AstraZeneca"s rating from "Sell" to "Neutral," maintaining a target price of 11,300 pence. Analyst Matthew Weston noted significant uncertainties in China but believes the pharmaceutical authority there will remain supportive of the company. However, below-consensus earnings estimates limit a more favorable outlook.
aktiencheck.de
United States Dollar Euro AstraZeneca PLC GBR Matthew Weston
TradFi, Market Report
06:51 20.11.2024
endometriosis treatment market projected to reach 3.1 billion by 2034
The endometriosis treatment market is projected to grow from USD 1.4 billion in 2023 to USD 3.1 billion by 2034, driven by increasing awareness and advancements in treatment options. Key trends include the rise of non-hormonal therapies and personalized medicine, while challenges such as high costs and limited access persist, particularly in developing regions. The competitive landscape features major players like AbbVie and Pfizer, alongside emerging companies innovating to meet unmet needs.
openPR.com
United States Dollar AstraZeneca PLC AbbVie Inc. Bayer AG Johnson & Johnson Pfizer Inc. USA DEU AbbVie Inc. Bayer AG AstraZeneca Johnson & Johnson Pfizer Inc. Show more
Healthcare, Market Report
16:12 19.11.2024
global hashimoto thyroiditis market projected to reach 12.6 billion by 2033
The global Hashimoto"s thyroiditis market is projected to grow from $8.3 billion in 2023 to $12.6 billion by 2033, with a CAGR of 4.26%. North America is expected to dominate the market, while Asia-Pacific will experience the fastest growth due to rising healthcare awareness and improved infrastructure. The tablet segment will hold the largest market share, driven by convenience and patient compliance.
Spherical Insights
United States Dollar Amgen Inc. Merck & Co., Inc. Novartis AG Sanofi Mylan N.V. Teva Pharmaceutical Industries Ltd. Bristol-Myers Squibb Company Takeda Pharmaceuticals Limited Company Bayer AG Pfizer Inc. Roche Holding AG AbbVie Inc. AstraZeneca PLC Eli Lilly and Company Glaxosmithkline plc ARG GBR FRA ITA KOR ZAF MEX USA BRA ESP SAU CAN QAT ARE JPN AUS DEU CHN RUS IND Pfizer Inc. AbbVie Inc. Mylan N.V. Inc. Merck & Co GlaxoSmithKline plc Show more
Healthcare, Market Report
04:38 19.11.2024
vaccine producers face stock declines amid controversial health secretary nomination
Shares of major vaccine manufacturers, including Pfizer and Moderna, fell significantly after Robert F. Kennedy Jr. was nominated as Secretary of Health and Human Services by President-elect Donald Trump. Kennedy's controversial anti-vaccine stance has raised concerns about its potential impact on public health policies and the vaccine market, which has been crucial for pharmaceutical companies. His history of promoting unfounded vaccine theories could undermine public trust and affect future health initiatives.
website
Moderna, Inc. GlaxoSmithKline Novavax, Inc. AstraZeneca PLC Pfizer Inc. USA Robert F. Kennedy Jr. Donald Trump Show more
Regulatory & Legal, Market Report
20:35 15.11.2024
analysts deem wall street's reaction to rfk jr appointment as overblown
Wall Street reacted negatively to Robert F. Kennedy Jr.'s appointment as head of the US Health and Human Services Department, causing significant drops in vaccine and healthcare stocks. Analysts believe the market's response may be exaggerated, noting that RFK Jr. has not proposed drastic changes and has stated he does not plan to eliminate vaccines. Concerns stem from his skepticism about the drug approval process and potential influence over key health agencies.
Yahoo Finance
Azerbaijani Manat UCB Pharma N.V. Merck & Co., Inc. Moderna, Inc. GSK plc AstraZeneca PLC Sanofi Pfizer Inc. USA Jared Holz Robert F. Kennedy Jr. Michael Yee Donald Trump Chris Schott Show more
Regulatory & Legal, Market Report
15:43 15.11.2024
Trump nominates Kennedy Jr. as health secretary causing healthcare stocks to drop
Donald Trump's nomination of Robert F. Kennedy Jr. as Secretary of Health has led to a decline in healthcare stocks, with major companies like Pfizer and Moderna experiencing significant drops. Kennedy, known for his vaccine skepticism, could influence national health policies at a time when vaccination rates are falling, raising concerns among public health experts. The World Health Organization emphasized the critical role of vaccines in global health, highlighting the potential implications of Kennedy's appointment.
Benzinga Italia
Azerbaijani Manat AstraZeneca PLC Pfizer Inc. Novavax, Inc. USA GBR Donald Trump Robert F. Kennedy Jr Show more
Regulatory & Legal, Market Report
15:30 15.11.2024
healthcare sector reacts negatively to robert f kennedy jr appointment
Robert F. Kennedy Jr.'s appointment as Health Minister in Donald Trump's administration has triggered a significant decline in pharmaceutical stocks across the US and Europe, with fears of potential drug price caps impacting investor confidence. Major companies like UCB and argenx saw sharp drops, reflecting broader concerns about the future of drug pricing and regulation under Kennedy's leadership. Analysts suggest that while there are constraints on his power, the potential for reduced regulations could lead to increased mergers and acquisitions in the sector.
L'Echo
United States Dollar Moderna, Inc. BioNTech SE Pfizer Inc. Genmab A/S Novavax, Inc. UCB SA AstraZeneca PLC Sanofi GSK plc USA CHE BEL Robert F. Kennedy Jr. Donald Trump Ashish Jha James Capretta Chris Meekins Show more
Finance & Economy, Market Report
15:24 15.11.2024
market movements and stock updates following election and health department changes
Traders are closely monitoring market movements following President-elect Trump's nomination of Robert F. Kennedy Jr. for HHS, raising vaccination concerns. Key biotech stocks like Moderna and Pfizer have seen declines, while the SPDR S&P Biotech ETF dropped 3%. In retail, Grocery Outlet and Warby Parker are up significantly, while Boeing's stock has fallen 15% since August amid labor disputes. Upcoming economic data is anticipated to influence market sentiment further.
CNBC
United States Dollar Merck & Co., Inc. Moderna, Inc. AstraZeneca PLC Pfizer Inc. Boeing Ron Baron Ted Decker Robert F. Kennedy Jr. Cathie Wood David Tepper Show more
Finance & Economy, Market Report
01:13 15.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.